Management of Elevated FSH in Females

Initial Diagnostic Confirmation

The primary management approach depends on determining whether elevated FSH indicates primary ovarian insufficiency (FSH >35 IU/L with amenorrhea ≥4 months) versus other causes, followed by hormone replacement therapy for confirmed cases and fertility counseling based on age and reproductive goals 1, 2
FSH measurement should be based on an average of three blood samples taken 20 minutes apart between cycle days 3-6 1
FSH >35 IU/L is considered abnormally elevated and suggests primary ovarian insufficiency 1, 3
Ensure the sample was not taken postictally (if seizure history exists) and was a morning resting sample 1
Document menstrual pattern for at least 6 months: amenorrhea is defined as no bleeding >6 months, oligomenorrhea as cycles >35 days 1

Obtain concurrent measurements of LH, prolactin, testosterone, mid-luteal progesterone, and thyroid function on cycle days 3-6 1, 3, 4
LH/FSH ratio >2 suggests PCOS rather than ovarian failure; LH >11 IU/L is abnormal; LH <7 IU/ml suggests hypothalamic amenorrhea 1
Prolactin levels >20 μg/L warrant evaluation for hypothyroidism or pituitary tumor 1, 4
Testosterone levels >2.5 nmol/l suggest PCOS or valproate effect 1, 3
Mid-luteal progesterone <6 nmol/l indicates anovulation 1, 4

Primary ovarian insufficiency (POI) is confirmed when FSH is elevated to menopausal range (>35 IU/L) on two separate occasions and amenorrhea has been present for ≥4 months in a woman <40 years old 2
Alternative diagnoses to consider based on hormonal patterns include PCOS, hypothalamic amenorrhea, hyperprolactinemia, and perimenopause in younger women 1, 3, 4

Hormone replacement therapy (HRT) is the cornerstone of management for confirmed primary ovarian insufficiency 7, 5, 6
Estrogen replacement options include oral micronized estrogen preparations, transdermal estrogen patches, and oral contraceptives (combined estrogen-progesterone) 5, 7
Progesterone is mandatory in women with an intact uterus to prevent endometrial hyperplasia from unopposed estrogen 7, 5, 6
Bone mineral density evaluation is essential in all hypogonadal patients due to increased osteoporosis risk 7, 5, 6

For women desiring future fertility, immediate referral to reproductive endocrinology for infertility evaluation and assisted reproduction consultation is recommended 7, 5, 6
Consider oocyte cryopreservation for patients wishing to preserve fertility options 7, 5, 6
Counsel menstruating women at risk of early menopause about the risks of delaying childbearing 7, 5, 6

Refer to endocrinology/gynecology for delayed puberty, persistently abnormal hormone levels, and confirmed hypogonadism requiring HRT management 7, 5, 6, 8
Refer to reproductive endocrinology for infertility evaluation, assisted reproduction consultation, and gestational surrogate discussion 7, 5, 6, 8

In cancer survivors or those exposed to gonadotoxic therapy, high-risk treatments include alkylating agents, pelvic radiation, total body irradiation, and myeloablative conditioning 2, 9, 7
Regular surveillance with FSH, LH, and estradiol is recommended starting at age 13 years in prepubertal survivors 7, 5
Risk of POI approaches 30% in survivors treated with both alkylating agents and abdominal-pelvic irradiation 7, 6
In women with epilepsy, PCOS prevalence is 10-25% in temporal lobe epilepsy patients, even without antiepileptic drugs 1, 4
Valproate can elevate testosterone and contribute to PCOS 1, 3
Hypothalamic amenorrhea occurs in 12% of women with temporal lobe epilepsy versus 1.5% in the general population 4, 3